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375ympathetic Nervous System Activation in HFohn S. Floras
eart failure (HF) due to left ventricular systolic dysfunction leads to generalized sympathetic
ctivation that is initially appropriate, but ultimately pathological. Floras reviews the multiple
nteractions between the sympathetic nervous system and symptoms and outcomes in patients
ith systolic dysfunction. The sympathetic activation reflects the net balance and interaction
etween appropriate reflex compensatory responses and excitatory stimuli that elicit adrenergic
esponses in excess of homeostatic requirements. These observations are incorporated into a
odel of cardiovascular neural regulation.TATE-OF-THE-ART PAPER386Palliative Care for Patients With HFarah J. Goodlin
n this state-of-the-art paper, Goodlin argues that symptoms and compromised quality of life
revail throughout the course of heart failure (HF) and should be specifically addressed with
alliative measures. The neurohormonal and catabolic derangements in HF that cause these
ymptoms are reviewed. Interventions for mitigating the effects of these derangements include
tandard HF care, leg-strengthening exercises, opioids, treatment of sleep-disordered
reathing, and interventions to address patient and family perception of control over their
llness. Strategies to facilitate communication about prognosis with HF patients and their
amilies are also reviewed.IEWPOINT397Standardizing Data Collection Will Strengthen HF Disease Management Programslexander M. Clark, Lori A. Savard, David R. Thompson
lark and colleagues review the data regarding the efficacy of heart failure (HF) disease-
anagement programs. Some recent trials have not demonstrated significant efficacy;
owever, this may be due to methodological issues that were not completely investigated.
esearch into HF management programs, which includes several meta-analyses, is hindered
ecause analyses, interventions, and comparisons are not sufficiently described, with complex
rograms over-simplified into a few interventions. Some of these flaws could be rectified
hrough a systematic survey of study authors to clarify aspects of previously published
esearch.(continued on page A-21)
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EEART FAILURE WITH PRESERVED EJECTION FRACTION402HFpEF Associated With Reduced Myocardial Energy Reservehanh T. Phan, Khalid Abozguia, Ganesh Nallur Shivu, Mahadevan Gnanadevan, Ibrar Ahmed,
ynne Williams, Girish Dwivedi, Kiran Patel, Paul Steendijk, Houman Ashrafian, Anke Henning,
ichael Frenneaux
han and colleagues performed magnetic resonance spectroscopy and radionuclide
entriculography at rest and during exercise in patients with heart failure with preserved
jection fraction (HFpEF) and healthy control patients. At rest, the time to peak left
entricular filling (nTPPF) was similar in patients and control patients; however, the cardiac
reatine phosphate/adenosine triphosphate ratio was reduced in HFpEF subjects, indicating
educed energy reserves. There were smaller augmentations in stroke volume during
ubmaximal exercise in HFpEF subjects, and nTTPF fell during exercise in control patients
ut increased in HFpEF patients. Integrating these observations, the authors speculate that
ynamic energy impairment may account for the slowing of left ventricular (LV) active
elaxation during exercise as well as the failure of LV contractile function to increase.EART FAILURE WITH PRESERVED EJECTION FRACTION410Ventricular Systolic Stiffening May Underlie HFpEF50 75 100 125 150
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%arry A. Borlaug, Carolyn S. P. Lam, Véronique L. Roger, Richard J. Rodeheffer, Margaret M. Redfield
orlaug and colleagues provide insights into the systolic function of patients with heart failure
ith preserved ejection fraction (HFpEF) using detailed echocardiographic studies of healthy
ontrol patients, hypertensive control patients without heart failure, and subjects with
FpEF. Load-independent indexes of chamber-level contractility (pre-load recruitable stroke
ork and wall stress-corrected endocardial fractional shortening) and of myocardial
ontractility (stress-corrected midwall fractional shortening) were found to be higher in the
ypertensive subjects than in control patients, but lower in those with HFpEF. These
ndings indicate that in spite of the apparently “preserved” ejection fraction, patients with
FpEF do have impaired contractile function.ditorial Comment: Samer S. Najjar, p. 419EART FAILURE AND DIABETES
422etrospective Study Suggests That Optimal
HbA1C Level is 7% to 8% for Patients With HFavid Aguilar, Biykem Bozkurt, Kumudha Ramasubbu, Anita Deswal
here is clear evidence that high glucose levels can be detrimental to cardiac function, but
ther studies have suggested that tight glucose control may increase mortality. Aguilar and
olleagues reviewed data from almost 6,000 subjects with a history of both heart failure (HF)
nd diabetes. The risk of subsequent death or HF hospitalization was then compared with
evels of glycosylated hemoglobin (HbA1C). At 2-year follow-up, the adjusted risk for death
as about 25% lower for those with a HbA1C 7.1% to 7.8%, compared with those with
ither higher or lower values. The association between mortality and HbA1C in diabetic
atients with HF appears U-shaped, with the lowest risk of death in those patients with
odest glucose control.ditorial Comment: Larry A. Weinrauch, Eldrin F. Lewis, p. 429
(continued on page A-24)
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s432Survival Benefit of Beta-Blockers Modified by Genetic Polymorphismsharon Cresci, Reagan J. Kelly, Thomas P. Cappola, Abhinav Diwan, Daniel Dries, Sharon L. R. Kardia,
erald W. Dorn II
ome studies have suggested that the benefits of -blocker therapy in patients with heart
ailure (HF) may not be seen in African Americans. Cresci and colleagues hypothesized that
his is due to different frequencies of 2 polymorphisms in the beta-adrenergic system. Almost
,500 subjects with HF were genotyped for the 1-adrenergic receptor (ADRB1)
rg389Gly and G-protein receptor kinase 5 (GRK5) Gln41Leu polymorphisms. As
xpected, these polymorphisms were more prevalent among African Americans, and
-blocker treatment increased survival in Caucasians but not African Americans. Further
nalysis showed that ADRB1 Gly389 was associated with decreased survival and GRK5
eu41 with improved survival. Subjects with the combination ADRB1 Gly389 GRK5
ln41Gln had a similar benefit from -blocker therapy regardless of race, confirming that
enetic differences in the -adrenergic receptor signaling pathway underlie the apparent
ifferences seen in African Americans and Caucasians.IGHT VENTRICULAR CARDIOMYOPATHY445Arrhythmogenic RV Dysplasia/Cardiomyopathy May Cause Ventricular Dyssynchronyaurens F. Tops, Kalpana Prakasa, Harikrishna Tandri, Darshan Dalal, Rahul Jain,
eronica L. Dimaano, David Dombroski, Cynthia James, Crystal Tichnell, Amy Daly, Frank Marcus,
artin J. Schalij, Jeroen J. Bax, David Bluemke, Hugh Calkins, Theodore P. Abraham
ops and colleagues studied the prevalence and mechanisms underlying right ventricular (RV)
yssynchrony in subjects with arrhythmogenic right ventricular dysplasia/cardiomyopathy
ARVD/C) using tissue Doppler echocardiography (TDE). Mechanical synchrony was
ssessed by measuring differences in time-to-peak systolic velocity (TSV) between the RV free
all, ventricular septum, and left ventricular lateral wall. RV dyssynchrony was present in
ne-half of the ARVD/C subjects; these subjects had a larger RV end-diastolic area and
ower RV fractional area change compared with ARVD/C patients without RV
yssynchrony. RV dyssynchrony may occur in ARVD/C patients, and is associated with RV
emodeling.CLINICAL RESEARCH ALVULAR HEART DISEASE452Beta-Blockers May Improve Outcomes in Patients With Severe ARnnati Sampat, Padmini Varadarajan, Rami Turk, Ashvin Kamath, Sumit Khandhar, Ramdas G. Pai
eta-blockers (BBs) are thought to be contraindicated in patients with severe aortic
egurgitation (AR) because slower heart rates increase the duration of diastole during which
R occurs. Yet, the neuroendocrine activation with AR is similar to that seen with systolic
ysfunction. Sampat and colleagues reviewed a large echocardiographic database and
dentified almost 800 subjects with severe AR. Nearly one-half of the subjects were on a BB.
ith a mean duration of follow-up 4.5 years, BB use was associated with higher survival
ates at 1 and 5 years, and was an independent predictor of better survival. This observational
tudy suggests that BB therapy may improve survival in patients with severe AR.Editorial Comment: Uri Elkayam, p. 458(continued on page A-26)
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cONGENITAL HEART DISEASE460Increasing Numbers of Hospitalizations for Adults With CHDlexander R. Opotowsky, Omar K. Siddiqi, Gary D. Webb
ver the last 50 years, the life expectancy of patients with congenital heart disease (CHD)
as greatly increased. Opotowsky and colleagues identified patients 18 years of age admitted
o an acute care hospital with an International Classification of Diseases-Ninth Revision code
esignating a CHD diagnosis. The number of adult CHD hospitalizations increased 100%
rom 1998 to 2005. Mean hospital charges per hospitalization rose 127%, and the estimated
otal national charges for these hospitalizations increased 357% to $3.16 billion. The number
f hospital admissions for adults with CHD in the U.S. more than doubled between 1998
nd 2005, and the costs of these hospitalizations almost quadrupled.CUTE CORONARY SYNDROMES468Fondaparinux Reduces Bleeding Compared With Enoxaparinanjit S. Jolly, David P. Faxon, Keith A. A. Fox, Rizwan Afzal, William E. Boden, Petr Widimsky,
. Gabriel Steg, Vicent Valentin, Andrez Budaj, Christopher B. Granger, Campbell D. Joyner,
usan Chrolavicius, Salim Yusuf, Shamir R. Mehta
he OASIS 5 trial demonstrated that fondaparinux reduced major bleeding by 50%
ompared with enoxaparin while preserving similar efficacy in reducing ischemic outcomes.
olly and colleagues performed this retrospective subgroup analysis to determine if this benefit
s affected by concurrent antiplatelet therapy with clopidogrel and/or glycoprotein (GP) IIb/IIIa
nhibitors. Subjects in the trial were randomized to either fondaparinux or enoxaparin, but the use
f GP IIb/IIIa inhibitors or thienopyridines was at the discretion of the treating physician. There
as a 40% reduction in major bleeding with fondaparinux in those treated with GP IIb/IIIa
hazard ratio [HR]: 0.61) and a similar reduction in those treated with thienopyridines (HR: 0.62).
n patients receiving GP IIb/IIIa inhibitors or thienopyridines, fondaparinux reduces major
leeding and improves net clinical outcome compared with enoxaparin.CUTE CORONARY SYNDROMES477Periprocedural MI Does Not Significantly Affect Outcomesbhiram Prasad, Bernard J. Gersh, Michel E. Bertrand, A. Michael Lincoff, Jeffrey W. Moses,
. Magnus Ohman, Harvey D. White, Stuart J. Pocock, Brent T. McLaurin, David A. Cox,
lexandra J. Lansky, Roxana Mehran, Gregg W. Stone
his study by Prasad and colleagues evaluated the relative impact of periprocedural and
pontaneously occurring myocardial infarction (MI) on survival following percutaneous
oronary interventions (PCIs). Subjects in the ACUITY trial were examined for
eriprocedural MI, defined as a rise in creatine kinase-myocardial band within 24 h post-
CI, and spontaneously occurring MI, which was not procedure-related and occurred within
he first year after enrollment. A periprocedural MI developed in 6.0% and a spontaneously
ccurring MI developed in 2.6%. Patients developing spontaneously occurring and
eriprocedural MIs had significantly higher unadjusted rates of mortality. After adjusting for
ifferences in baseline and procedural characteristics, spontaneously occurring MI was a
owerful independent predictor of subsequent mortality (hazard ratio: 7.5), whereas
eriprocedural MI was not. Among patients with acute coronary syndromes undergoing PCI,
eriprocedural MI is a marker of baseline risk, atherosclerosis burden, and procedural
omplexity, but does not have independent prognostic significance.
